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Abstract
Background: Venetoclax, a small molecule BH3 mimetic which inhibits the anti-apoptotic protein Bcl-2, and
idasanutlin, a selective MDM2 antagonist, have both shown activity as single-agent treatments in pre-clinical
and clinical studies in acute myeloid leukemia (AML). In this study, we deliver the rationale and molecular
basis for the combination of idasanutlin and venetoclax for treatment of p53 wild-type AML.
Methods: The effect of idasanutlin and venetoclax combination on cell viability, apoptosis, and cell cycle
progression was investigated in vitro using established AML cell lines. In vivo efficacy was demonstrated in
subcutaneous and orthotopic xenograft models generated in female nude or non-obese diabetic/severe
combined immunodeficiency (NOD/SCID) mice. Mode-of-action analyses were performed by means of cell
cycle kinetic studies, RNA sequencing as well as western blotting experiments.
Results: Combination treatment with venetoclax and idasanutlin results in synergistic anti-tumor activity compared
with the respective single-agent treatments in vitro, in p53 wild-type AML cell lines, and leads to strongly superior
efficacy in vivo, in subcutaneous and orthotopic AML models. The inhibitory effects of idasanutlin were cell-cycle
dependent, with cells arresting in G1 in consecutive cycles and the induction of apoptosis only evident after cells had
gone through at least two cell cycles. Combination treatment with venetoclax removed this dependency, resulting in
an acceleration of cell death kinetics. As expected, gene expression studies using RNA sequencing showed significant
alterations to pathways associated with p53 signaling and cell cycle arrest (CCND1 pathway) in response to idasanutlin
treatment. Only few gene expression changes were observed for venetoclax treatment and combination treatment,
indicating that their effects are mediated mainly at the post-transcriptional level. Protein expression studies
demonstrated that inhibition of the anti-apoptotic protein Mcl-1 contributed to the activity of venetoclax and
idasanutlin, with earlier inhibition of Mcl-1 in response to combination treatment contributing to the superior
combined activity. The role of Mcl-1 was confirmed by small hairpin RNA gene knockdown studies.
Conclusions: Our findings provide functional and molecular insight on the superior anti-tumor activity of
combined idasanutlin and venetoclax treatment in AML and support its further exploration in clinical studies.
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Background
Acute myeloid leukemia (AML) is the most common
acute leukemia in adults and, although high remission
rates are achieved following induction chemotherapy,
the majority of patients eventually relapses and becomes
resistant to treatment [1]. There have been few changes
in standard induction therapy and response rate over the
past three decades, particularly for older patients who
are ineligible for intensive chemotherapy or allogeneic
stem cell transplantation [2–4]. Thus, the development
of novel therapeutics based on an improved understand-
ing of the molecular pathogenesis of AML has been a
major focus to address this unmet need.
Idasanutlin (RG7388) and venetoclax (ABT-199/
GDC-0199) have each shown significant activity in
AML models in pre-clinical studies [5, 6], and each
compound is currently under evaluation in patients
with AML in phase I and II clinical trials as mono-
therapy or in combination with chemotherapy (study
identifiers: NCT01773408; NCT01994837; NCT02203773;
NCT02287233). In addition, venetoclax has recently been
granted breakthrough designation by United States Food
and Drug Administration (FDA) for treatment of relapsed
and refractory chronic lymphoid leukemia (CLL) with 17p
deletion [7].
Idasanutlin and venetoclax have complementary mecha-
nisms of action. Idasanutlin is a second-generation,
nutlin-class, orally bioavailable, selective mouse double
minute 2 homolog (MDM2) antagonist [8]. MDM2 is an
important negative regulator of the p53 tumor suppressor
[9] and is expressed at high levels in a large proportion of
AML [10, 11]. Wild-type p53 is expressed in over 80 % of
AML cases; thus, inhibition of the interaction between
MDM2 and p53 can re-establish the p53 pathway in AML
cells resulting in cell cycle arrest and induction of apop-
tosis [10, 12, 13]. Venetoclax (GDC-0199/ABT-199) is an
orally bioavailable novel small-molecule BCL-2 homolog
domain 3 (BH3) mimetic, designed to selectively inhibit
the anti-apoptotic protein Bcl-2. High Bcl-2 expression in
AML is associated with resistance to chemotherapy and
reduced likelihood of achieving complete remission
[13–16]. Pre-clinical studies show that venetoclax has
significant anti-tumor activity in AML models and
that venetoclax-dependent inhibition of Bcl-2 can prime
AML cells for responsiveness to chemotherapy [17].
The re-establishment of complementary key tumor
suppressor and apoptotic pathways through combination
treatment with venetoclax and idasanutlin may increase
anti-tumor activity in AML cells. Direct activation of
mitochondrial apoptosis through Bcl-2 inhibition may
be enhanced by p53-dependent cell cycle arrest, p53-
induced transcription of the pro-apoptotic Bcl-2 gene
Bax, and direct binding and inhibition of anti-apoptotic
Bcl-2 proteins.
However, combined MDM2 and Bcl-2 inhibition for
AML treatment has not been clinically investigated yet.
In this study, we sought to confirm the superior activity
of this combination and to establish a pre-clinical ration-
ale for its further exploration in clinical studies. We
therefore assessed the anti-tumor effects of dual
MDM2/Bcl-2 inhibition with the small-molecule inhibi-
tors idasanutlin and venetoclax in p53 wild-type AML
models and explored the mechanism of action contribut-
ing to their synergistic activity in vitro through cell-cycle
analysis, RNA sequencing (RNAseq), and time-course
protein expression analysis. Moreover, we confirmed the
superior activity of the combination treatment in sub-
cutaneous and orthotopic AML xenograft models.
Methods
Reagents
Lyophilized idasanutlin and venetoclax were obtained
from Roche Innovation Center Basel and Genentech
Inc., South San Francisco, respectively. A stock solution
of each was prepared in dimethyl sulfoxide (DMSO),
and serial dilutions were prepared in culture medium
prior to each experiment; the final DMSO concentration
was less than 0.2 % (v/v) in all experiments.
Cell lines and culture conditions
The MV4-11 and MOLM-13 p53 wild-type AML cell
lines and the p53 mutant HL-60 promyelocytic cell
line were obtained from the Roche Pharma Research &
Early Development (pRED) cell bank (Roche Diagnos-
tics GmbH). The p53 wild-type/NPM mutant OCI-AML-
3 cell line was obtained from the Roche pRED CELLO cell
bank (Roche Diagnostics GmbH). MV4-11 and MOLM-
13 cells were cultured in RPMI-1640 supplemented with
20 % fetal calf serum (FCS; Gibco), HL-60 cells were
cultured in RPMI-1640 supplemented with 10 % FCS, and
OCI-AML-3 cells were cultured in alpha-MEM supple-
mented with 20 % FCS. Cultures were maintained at
37 °C, with 7 % CO2 in a humidified atmosphere. Cell
line identity was confirmed by short tandem repeats-
polymerase chain reaction (STR-PCR) genotyping using
the QIAGEN Investigator IDplex Plus Kit (QIAGEN
cat. no. 381625).
Cell viability and apoptosis measurement
Cell cultures were treated with idasanutlin alone
(0.6–2000 nM), venetoclax alone (0.6–2000 nM), or
both agents combined for 72 h. Viability was mea-
sured using CellTiter-Glo® (Promega), as per manufac-
turer’s instructions, with luminescence measured
using the Infinite® F200 microplate reader (Tecan). In
short hairpin RNA (shRNA) experiments, viability was
measured by trypan blue exclusion using the Cedex
HiRes automated analyzer (Roche Diagnostics).
Lehmann et al. Journal of Hematology & Oncology  (2016) 9:50 Page 2 of 13
For measurement of apoptosis, cells were stained
with Annexin-V-Fluos staining buffer (1 μL/sample
Annexin-V-Fluos [Roche Diagnostics GmbH], 2 ng/μL
Hoechst 33258, and 400 nM CaCl2, prepared in culture
medium) and incubated on ice for 15 min in the dark.
Fluorescence was analyzed at 4 °C on the LSRII flow
cytometer (BD Biosciences).
Data for viability and apoptosis measurements were
analyzed using XLfit® for Excel (Microsoft Corporation).
Flow cytometric data were analyzed using FlowJo soft-
ware versions 7.6.5 and 10.0.7 (Treestar).
Relative and absolute half maximal inhibitory concentra-
tion (IC50) values were calculated for each treatment, with
relative IC50 corresponding to the mid-point between the
upper and lower plateaus of the response curve and abso-
lute IC50 representing 50 % of the control.
To determine synergistic effects between idasanutlin and
venetoclax, combination indices were calculated as per
Loewe and Muchnik [18] using the following equation:




where ICxA and ICxB are the concentration of com-
pounds A and B required individually for effect x (in this
study x = relative IC50) and CA and CB are the concen-
tration of compounds A and B required in combination
to achieve the same effect x. Values less than 1 indicate
synergy.
AML xenograft models
Subcutaneous and orthotopic xenograft models were
generated in female nude or non-obese diabetic/severe
combined immunodeficiency (NOD/SCID) mice. All ex-
periments were conducted by Charles River Discovery
Research Services (CR-DRS) in accordance with the rec-
ommendations of the Guide for Care and Use of Labora-
tory Animals [19] with respect to restraint, husbandry,
surgical procedures, feed and fluid regulation, and veter-
inary care. The animal care and use program at CR-DRS
is accredited by the Association for Assessment and Ac-
creditation of Laboratory Animal Care International
(AAALAC).
For the subcutaneous model, MV4-11 cells (1 × 107)
were injected subcutaneously with Matrigel™ Basement
Membrane Matrix (BD Biosciences) into the right flanks
of 7-week-old mice. On day 12 post-inoculation, mice
(n = 10 per group) were stratified randomly based on pri-
mary tumor size with a median tumor volume (prior to
treatment) of approximately 100–150 mm3. Idasanutlin
(30 mg/kg orally) and venetoclax (100 mg/kg orally)
were administered daily for 21 days alone or in com-
bination. Tumor volumes ([length × width]2/2) were
measured by calipers twice weekly and tumor growth
inhibition relative to control animals was calculated
as follows:
Tumor growth inhibition ¼ 1− T−T0ð Þ= C−C0ð Þ½ ð Þ  100
where T is the tumor volume in the treated group at
measurement, T0 is the tumor volume in the treated
group at baseline, C is the tumor volume in the control
group at measurement, and C0 is the tumor volume in
the control group at baseline.
The MV4-11 and MOLM-13 orthotopic models were
established by intravenous inoculation of 1 × 107 and
5 × 106 cells, respectively. Ten-week-old mice were pre-
treated with cyclophosphamide (150 mg/kg, intraperito-
neally), cells were injected into the tail vein, and mice
were distributed randomly into four groups (n = 10 per
group). Treatment was initiated 22 days after inoculation
of MV4-11 cells and 3 days after inoculation of MOLM-
13 cells. In both tumor studies, idasanutlin (30 mg/kg
orally) and venetoclax (100 mg/kg orally) were adminis-
tered daily for 21 days alone or in combination. Animals
were monitored daily for clinical symptoms and adverse
events.
A time-to-event (TTE) analysis was conducted until
day 78 post-inoculation in the MV4-11 model and
day 48 post-inoculation in the MOLM-13 model. The
event was death or moribundity due to disseminated
leukemia. Any animal that did not reach the endpoint
was euthanized at the end of the study and assigned
a TTE value of 78 days for the MV4-11 model or
48 days for the MOLM-13 model. Any animal that
died from non-tumor burden-related causes was ex-
cluded from the analysis. A TTE value was recorded
for each assessable animal, and the median TTE was
calculated for each group.
The percentage increase in lifespan (ILS) versus the
vehicle control was calculated as:
ILS ¼ T−Cð Þ
C
 100%
where T is the median survival of the treatment group
and C is the median survival of the control group.
Cell cycle analysis
MV4-11 and MOLM-13 cells were treated with idasanu-
tlin and venetoclax alone or in combination for 72 h
(0.6–2000 nM). At the start of the final 24 h of incuba-
tion, 5-bromo-2-deoxyuridine (BrdU; Sigma) was added
to cultures at a concentration of 80 μM. Culture
medium was also supplemented with 80 μM deoxycyti-
dine (Sigma) at this point to minimize disturbance to
the nucleotide pathway. Prior to flow cytometric ana-
lysis, cells were washed twice in ice-cold DNA-staining
buffer (100 mM Tris pH 7.4, 154 mM NaCl, 1 mM
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CaCl2, 0.5 mM MgCl2, 0.1 % NP40, and 0.2 % bovine
serum albumin) and incubated in DNA-staining buffer
containing 10 U/mL RNase (Roche Diagnostics GmbH)
and 1.5 μg/mL Hoechst 33258 for 15 min at 37 °C. Pro-
pidium iodide (PI) was added to a final concentration of
1.5 μg/mL, and cells were incubated on ice for 15 min.
Fluorescence was analyzed on the LSRII flow cytometer,
and data were analyzed using FlowJo software versions
7.6.5 and 10.0.7.
Gene expression analysis
For mRNA (poly-A) RNAseq studies, MOLM13 cells
were treated with idasanutlin (100 nM) and veneto-
clax (100 nM) alone or in combination for 6 h. High
molecular weight RNA (>200 base pairs) was ex-
tracted from four biologic replicates using the
RNeasy® Mini Kit (QIAGEN®) as per manufacturer’s
instructions. Residual genomic DNA was removed
during the extraction using the RNase-free DNase set
(QIAGEN®). RNA quality was analyzed using
Eukaryote Total RNA Nano chips (Agilent Technolo-
gies), and all samples used for analysis had an RNA
integrity number >8. RNAseq libraries were generated
from 1 μg total RNA using the TruSeq® RNA Sample
Preparation v2 kit (Illumina®) as per manufacturer’s
instructions. Sequencing libraries were quantified
using the Kapa Library Quantification kit (Kapa Bio-
systems), and quality was assessed on the Agilent
Bioanalyzer using DNA 1000 chips (Agilent Technolo-
gies). Libraries were sequenced on the HiSeq® 2500
sequencer (Illumina) for 2 × 50 cycles using the Tru-
Seq® PE Cluster Kit v3-cBot-HS and TruSeq® SBS Kit
v3-HS sequencing reagents (Illumina®). Each lane was
spiked with the PhiX Control v3 library (Illumina®) at
a final concentration of 1 % (v/v) as a sequencing
control.
Sequencing reads were first aligned to the human
protein coding transcriptome (as defined by Ensembl
v73 [http://www.ensembl.org]) using Bowtie 2 [20].
In a second step, all reads not mapping to the hu-
man transcriptome were aligned to the human gen-
ome (hg19) using Bowtie 2. For both mapping steps,
default sensitivity settings were used. Gene expres-
sion was profiled using in-house tools, and reads per
kilobase per million reads (RPKM) were computed as
previously described using in-house software [21].
Differential gene expression was computed using
DESeq [22]. Genes with an absolute log2 ratio >1
(absolute fold change >2) versus the DMSO control
and a false discovery rate corrected P value <0.01
were considered differentially expressed. Functional
annotation and analysis of altered pathways and
functions was performed using Ingenuity® Pathway
Analysis (QIAGEN®).
shRNA analysis
MV4-11 cells (5 × 105) were transduced with MIS-
SION® non-specific or Mcl-1-targeting shRNA lenti-
viral particles (Sigma) in the presence of polybrene
(10 μg/mL); target sequences are listed in Additional
file 1. Puromycin (2 μg/mL) was added after 48 h to
select for positive transductants, and cells were sam-
pled for viability and protein expression analysis on
the following day.
Western blotting
Cells were lysed in RIPA buffer (Sigma), lysates were
loaded onto NuPAGE® 4–12 % Bis-Tris Precast
Protein Gels (Life Technologies), and proteins were
separated and transferred to nitrocellulose mem-
branes (Life Technologies). Membranes were blocked
with 5 % (w/v) milk powder in Tris-buffered saline
with Tween 20 and incubated with Mcl-1, cleaved
caspase-3 (Asp175), or ß-actin primary antibodies,
followed by incubation with horseradish peroxidase
(HRP)-conjugated secondary antibodies (Cell Signal-
ing Technology). Bands were detected using Super-
Signal® Chemiluminescent HRP Substrate (Thermo
Fisher Scientific).
Statistical analyses
For viability and apoptosis assays, at least three biologic
replicates were analyzed. The data presented are the
mean values of one representative experiment. Mean
values and standard deviations were calculated using
Excel (Microsoft Corporation).
For the MV4-11 subcutaneous model, primary tumor
growth data were baseline corrected against tumor vol-
ume at the start of treatment, based on ratios. Adjusted
data were analyzed using non-parametric methods due
to an asymmetric distribution. Treatment-to-control ra-




where V is tumor volume. Two-sided non-parametric
confidence intervals (CIs; 1 − α) were also calculated [23].
For the MV4-11 and MOLM-13 orthotopic models,
the date of the last measurement was used for analysis
of median and overall survival and the generation of
Kaplan-Meier plots. Treatment groups were compared
using a pairwise log-rank test with a multiple test level
of 0.00833 considered statistically significant.
Statistical analyses for all in vivo studies were per-
formed using SAS-JMP version 8.1 (SAS Inc., 2007).
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Results
Combined treatment with idasanutlin and venetoclax
shows synergistic effects in AML cell lines in vitro
The effects of single-agent and combination therapy
with idasanutlin and venetoclax were assessed in four
AML cell lines exposed to the inhibitors for 72 h. The
MV4-11 and MOLM-13 cell lines carry the wild-type
TP53 gene, and the OCI-AML-3 cell line carries wild-
type TP53 and a nucleophosmin (NPM) mutation. NPM
mutant AML accounts for ~35 % of AML in adults [24].
The HL-60 AML cell line, which carries deletions in
both TP53 alleles, was used as a control to monitor non-
specific effects of the MDM2 antagonist idasanutlin.
Viability was assessed based on adenosine triphosphate
(ATP) concentration, as a measure of metabolically active
cells. In viability studies (Fig. 1), dose-dependent effects
were seen in the MV4-11 (Fig. 1a) and MOLM-13 (Fig. 1b)
p53 wild-type cell lines for single-agent treatment with
both inhibitors. Relative and absolute IC50 values were cal-
culated for each treatment. For MV4-11 cells, relative IC50
values for idasanutlin and venetoclax were 55 and 18 nM,
respectively, and absolute IC50 values were 51 and 12 nM,
respectively. For MOLM-13 cells, the respective relative
IC50 values were 35 and 20 nM, while absolute IC50 values
were 31 and 16 nM. In both cell lines, combination treat-
ment was synergistic, with a calculated combination index
of 0.72 for MV4-11 cells and 0.59 for MOLM-13 cells
(values <1 indicate synergy), corresponding to relative
IC50 values of 8 and 7 nM, respectively.
Venetoclax had little effect on the viability of the NPM
mutant OCI-AML-3 cell line (resistance to Bcl-2 inhibi-
tors has been seen previously in this cell line; data not
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Fig. 1 Viability of a MV4-11, b MOLM-13, c OCI-AML-3, and d HL60 cells treated with idasanutlin and venetoclax alone and in combination for
72 h. CellTiter-Glo® assay (Promega) was used to determine the cellular viability. Data are displayed as mean plus standard deviation calculated
from at least three biological replicates. In MV4-11 cells (a), combination treatment led to synergistic effects with a combination index (CI) of 0.72
and a relative IC50 of 8 nM compared to 55 and 18 nM for idasanutlin and venetoclax single treatment, respectively. In MOLM-13 cells (b), the
calculated CI was 0.59 with an IC50 of 7 nM for the combination as opposed to single treatment with idasanutlin (IC50, 35 nM) and venetoclax (IC50,
20 nM). OCI-AML-3 cells were resistant to venetoclax (c), while p53 mutated HL-60 cells did not react up to 2 μM idasanutlin as expected (d)
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shown); hence, there was no notable difference between
single-agent idasanutlin (relative/absolute IC50, 164/147
nM) and the combination treatment for this cell line
(relative/absolute IC50, 142/133 nM). Non-specific ef-
fects were not observed for idasanutlin treatment in the
p53 mutant HL-60 line, although venetoclax induced
substantial cell death (relative/absolute IC50, 4/4 nM).
The results of cell viability studies were supported by
apoptosis analyses using Annexin-V-Hoechst staining
(Fig. 2), showing strongly superior effects of the combin-
ation treatment for MV4-11 (relative/absolute IC50,
combination, 19/10 vs. 203/114 nM, idasanutlin single
treatment) and MOLM-13 (relative/absolute IC50, com-
bination, 20/11 vs. 102/100 nM, idasanutlin single treat-
ment). Again, idasanutlin did not have any effect on p53
mutated HL-60 cells. The OCI-AML-3 cell line did not
respond to venetoclax or idasanutlin alone, but was
highly sensitive to the combination treatment (relative/
absolute IC50, 142/108 nM). Given that the viability
analyses were based on ATP measurement, the reduc-
tion in ATP content relative to the control in this cell
line was likely due to G1 cell cycle arrest as opposed to
direct cell death, leading to the discrepancy between the
viability and apoptosis analyses. Staining of these cells
with Hoechst 33258 and PI confirmed G1 cell cycle
arrest in idasanutlin- and combination-treated cells.
Furthermore, side scatter analysis showed a large pro-
portion of aberrant nuclei with reduced Hoechst
33258 fluorescence, indicating DNA cleavage and con-
firming that these cells were in the early stages of
apoptosis (Additional file 2).
Notably, for venetoclax-induced cell death, the pro-
portion of apoptotic cells measured in the Annexin-
V-Hoechst studies did not correspond directly with
the results of the viability studies in any of the cell
lines analyzed (with the exception of the OCI-AML-3
cell line). This appears to be due to faster apoptosis
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Fig. 2 Endpoint apoptosis measurement of a MV4-11, b MOLM-13, c OCI-AML-3, and d HL60 cells following treatment with idasanutlin and vene-
toclax alone and in combination for 72 h. Binding of annexin-V-fluos to phosphatidylserine on the surface of apoptotic cells was assessed using
flow cytometry. Data are displayed as mean plus standard deviation calculated from at least three biological replicates. Combination of both com-
pounds led to strongly enhanced cell death induction as compared to single treatment in MV4-11 (a) and MOLM-13 (b) cells. In OCI-AML-3 cells
(c), idasanutlin displayed only minor effects, while the combination treatment led to strongly enhanced cell death. Control cell line HL-60 did not
respond to idasanutlin treatment (d)
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treatment. Given that apoptosis measurement is an
endpoint determination, it is possible that Annexin-
positive, and even Annexin-Hoechst-positive, cells
were missed in this analysis as they had already been
degraded.
Combined treatment with idasanutlin and venetoclax
shows superior anti-tumor effects in vivo
The activity of idasanutlin and venetoclax were further
assessed in subcutaneous and orthotopic AML xenograft
models. In the MV4-11 subcutaneous model, tumor
growth inhibition relative to the vehicle control group
was 0 % for venetoclax (no inhibition vs. control, TCR
0.89, CI, 0.50–2.10) and 30 % for idasanutlin (TCR 0.5,
CI, 0.26–0.98). Compared with the single-agent treat-
ments, combination treatment resulted in superior
tumor growth inhibition (>100 %) and notably partial
tumor regression of 55 % (TCR 0.03, CI, 0.02–0.07) rela-
tive to the control (Fig. 3a).
In a TTE analysis of the MV4-11 orthotopic model,
the median survival of the mice post-inoculation was
38.5 days for mice treated with the vehicle control
(Fig. 3b). In comparison, the median survival was 38 days
with venetoclax, 52 days with idasanutlin, and enhanced
to 70 days with combination treatment. This corre-
sponded to ILS values of −1 % for venetoclax, 35 % for
idasanutlin, and 82 % for combination treatment. The
median and overall survival was significantly better for
combination treatment than for each of the single-agent
treatments (P < 0.0001 for both).
In the MOLM-13 orthotopic model, the median sur-
vival of the mice post-inoculation was 26 days with
venetoclax, 23 days with idasanutlin, and a superior
45 days with combination treatment, compared with
21 days for the vehicle control (Fig. 3c). The correspond-
ing ILS values were 24 % for venetoclax, 10 % for idasa-
nutlin, and 114 % for combination treatment. In terms
of efficacy, median and overall survival was significantly
better for combination treatment than single-agent treat-
ment (P < 0.0001).
For all in vivo studies, treatments were well tolerated
as indicated by no significant loss of body weight
(>20 %) for the duration of the study.
Combination treatment leads to accelerated cell death
kinetics in vitro
Once the activity of idasanutlin and venetoclax had been
assessed in cell culture and human AML xenograft
models, exploratory studies were conducted to deter-
mine the cellular mechanisms contributing to their com-
bined effects. BrdU analysis using Hoechst 33258 and PI
was conducted to analyze changes in cell cycle kinetics
of MOLM-13 and MV4-11 cells in response to treat-
ment. BrdU is incorporated into DNA during replication
and quenches fluorescence upon subsequent staining
with Hoechst, giving a measure of cell division over
time. Simultaneous PI staining for DNA content
shows cell cycle progression. Figure 4 shows that cells
treated with the DMSO control (vehicle) progressed
through up to three cell cycles over the 24 h study
period as measured by BrdU/Hoechst quenching.
Treatment with idasanutlin (60 nM) induced G1 cell
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Fig. 3 Tumor growth inhibition in a MV4-11 subcutaneous model
and TTE analysis of survival in b MV4-11 and c MOLM-13 orthotopic
models (n = 10 mice per group). Combination treatment resulted in
superior anti-tumor activity and enhanced survival. See text for
details. TTE time-to-event
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replication. Minor nuclear fragmentation indicating
apoptosis, evident from a sub-G1 population, was
only observed in the G1 phase of the second cycle
onwards (Fig. 4). However, treatment with 60 nM
venetoclax induced nuclear fragmentation in both the
first and second cell cycles (Fig. 4). Combination
treatment led to high levels of nuclear fragmentation
from cells arrested in the G1 phase of the first cycle
and, to a lesser extent, the second cycle (Fig. 4).
Hence, viable but non-proliferating cells, arrested in
G1 by idasanutlin, are more vulnerable to venetoclax
treatment, resulting in enhanced and accelerated cell
death kinetics. The observed effects were similar be-
tween MV4-11 and MOLM-13 cell lines (Fig. 4).
Gene expression analysis confirms TP53 pathway
activation by idasantulin, while venetoclax treatment
does not result in transcriptional changes
RNAseq analysis was performed to measure gene ex-
pression changes in response to inhibitor treatment.
MOLM-13 cells were exposed to idasanutlin (100 nM)
and venetoclax (100 nM) alone or in combination for
6 h, and differential gene expression was analyzed.
Overall, more than 45 million reads were sequenced
for each sample. In comparison with the DMSO control,
substantially more genes showed differential expression
following idasanutlin and combination treatment than
venetoclax treatment. Overall 46, 363, and 183 genes
were differentially expressed in response to venetoclax,
idasanutlin, and combination treatment, respectively.
Upstream regulator analysis using Ingenuity pathway
software predicted TP53 pathway activation as expected
and CCND1 pathway inhibition indicating G1 arrest as
the most significant changes following idasanutlin treat-
ment and also following combination treatment (Fig. 5).
No significantly altered pathways were identified in re-
sponse to venetoclax treatment. There were no obvious
differences in gene expression between the idasanutlin-
treated cells and combination-treated cells that would
explain the synergistic effects of combination treatment
in vitro, confirming that venetoclax directly acts on Bcl-
2 function rather than on gene expression.
Combination treatment leads to accelerated Mcl-1 down-
regulation and caspase-3 activation
As expected, western blot analysis of MOLM-13 cells
showed that p53 protein levels increased with the dur-
ation of exposure to idasanutlin and combination treat-
ment, but not with venetoclax treatment (Fig. 6a).
Cleaved caspase-3, demonstrating execution of apop-
tosis, was detected after 16 h of exposure to idasanutlin
and after 7 h exposure to venetoclax, although expres-
sion levels were lower following venetoclax treatment
compared with idasanutlin-treated cells (16 h). Combin-
ation treatment with idasanutlin and venetoclax resulted
in increased detection of cleaved caspase-3 versus
single-agent therapy with either compound from 7 h of
exposure. In cells treated with idasanutlin alone, Mcl-1
Fig. 4 BrdU analysis of cell-cycle kinetics in MOLM-13 and MV4-11 cells treated with idasanutlin and venetoclax alone and in combination for
72 h. BrdU was added for the last 24 h of the experiment as described in the “Methods” section. Populations residing in G1, S, and G2/M phases
are indicated as an example for MOLM-13 vehicle-treated cells. Sub G1 represents nuclear fragmentation as a consequence of cell death. Vehicle
(DMSO)-treated cells displayed normal proliferation, with MOLM-13 cells reaching the third and MV4-11 cells reaching the second cycle. Treatment
with idasanutlin induces cell cycle arrest and minor nuclear fragmentation from the G1 phase of the second cell cycle (sub G1, arrows). Treatment
with venetoclax did not affect cell cycle progression, but induced nuclear fragmentation mainly from the G1 phase of the first cycle (arrows).
Combination treatment results in remarkably enhanced nuclear fragmentation from the G1 phase of the first cell cycle onwards with few viable
cells remaining
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was still detected after 7 h exposure but was no longer
detectable after 16 h, indicating treatment-associated
downregulation (Fig. 6a). Single-agent treatment with
venetoclax did not inhibit Mcl-1 expression (Fig. 6a).
Mcl-1 was not detected at either timepoint following
combination treatment, indicating earlier effects on
Mcl-1 expression with the combination treatment
(Fig. 6a). In MV4-11 cells, Mcl-1 expression was de-
tected at 7 h post-treatment with both inhibitors and at
very low levels 16 h post-treatment (Fig. 6b). Consistent
with findings in the MOLM-13 cell line, Mcl-1 was not
detected in MV4-11 at either timepoint with the
combination treatment again indicating accelerated cell
death kinetics.
shRNA knockdown of Mcl-1 gene expression confirms
that Mcl-1 is necessary for AML survival
The role of Mcl-1 in mediating the synergistic effects of
idasanutlin and venetoclax in vitro was verified by
shRNA experiments in MV4-11 cells (Fig. 7). The MV4-
11 cell line was used for this study due to lower expres-
sion of Mcl-1 versus MOLM-13 cells (Fig. 6). Transduc-
tion of cells with Mcl-1-targeting shRNAs leads to Mcl-1
gene knockdown to varying extents in comparison with
the non-specific control (Fig. 7a). This led to decreases
in cell viability, with the extent of the decreases corre-
sponding to the extent of Mcl-1 knockdown (Fig. 7b).
Discussion
Reconstitution of p53 tumor-suppressor activity, through
treatment with the MDM2 antagonist idasanutlin, and
induction of mitochondrial apoptosis, through specific
Bcl-2 inhibition with the BH3 mimetic venetoclax, led to
anti-tumor effects in both in vitro and in vivo human
xenograft models of AML. The effects of these com-
pounds were significantly enhanced through combin-
ation treatment, with combination indices indicating a
synergistic effect in vitro. Studies to determine the
mechanism(s) underlying this synergy showed that the











































Fig. 5 Upstream regulator analysis using Ingenuity pathway software in MOLM-13 cells exposed to idasanutlin (100 nM) for 6 h predicted a TP53
pathway activation and b CCND1 pathway inhibition. Bcl-2 inhibition by venetoclax did not result in changes of gene transcription
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direct induction of mitochondrial apoptosis lead to im-
mediate and potent cell death. Western blot analysis
identified that Mcl-1 inhibition is a key contributor to
these effects, and earlier Mcl-1 inhibition is seen in re-
sponse to idasanutlin/venetoclax combination treatment,
correlating with accelerated cell death kinetics.
Both nutlins and BH3 mimetics have shown prom-
ise in pre-clinical and clinical studies [5, 6, 25–29].
Idasanutlin and venetoclax represent clinically opti-
mized molecules within their respective compound
classes. Idasanutlin shows increased specificity and ac-
tivity, with lower dosage requirements, compared with
preceding nutlin-class compounds [5, 8]. Venetoclax
has enhanced specificity compared with earlier BH3
mimetics (such as ABT-737 and the related clinical-
grade compound navitoclax), which interact with the
BH3 domains of Bcl-2, Bcl-xL, and Bcl-w. Venetoclax
specifically inhibits Bcl-2 and therefore is not associ-
ated with the dose-limiting thrombocytopenia result-
ing from Bcl-xL inhibition [30].
Our data show that exposure of human AML cell lines
in vitro to single-agent venetoclax or idasanutlin induced
cell death without off-target effects, with enhanced
apoptotic activity seen when cells were treated with the
two agents in combination. Discrepancies in the levels of
inhibition between the cell viability and apoptosis studies
are likely due to the nature of the assays used and
highlight the different modes of action of the two inhibi-
tors. The viability studies (Fig. 1) were based on ATP
measurement as an indicator of metabolic activity, while
apoptosis studies (Fig. 2) measured phosphatidyl serine
exposure and membrane permeability. Thus, the viability
assays will detect cell cycle arrest in addition to apop-
tosis. For idasanutlin, cells became arrested in the G1
phase of the cell cycle initially before induction of apop-
tosis in subsequent cycles (Fig. 4). This is illustrated in
the OCI-AML-3 cell line where there was no difference
observed between idasanutlin and combination treat-
ment in viability studies based on ATP concentration.
However, in apoptosis studies, there was little cell death
in response to idasanutlin, indicating that the effects
seen in the viability studies were due to cell cycle arrest
as opposed to cell death (Figs. 1 and 2 and Additional
file 2). In the MV4-11 and MOLM-13 cell lines, induc-
tion of cell death was initiated immediately in response
to venetoclax treatment and this may actually have led
to some apoptotic cells being missed by the assay. This
difference in cell death kinetics between the two inhibi-
tors was confirmed by Western blotting analysis of
cleaved caspase-3 expression, which shows accelerated
induction of apoptosis in response to venetoclax versus
idasanutlin (Fig. 6).




















































Fig. 6 Western blot analysis of a p53, cleaved caspase-3, and Mcl-1
protein expression in MOLM-13 cells and b Mcl-1 protein expression
in MV4-11 cells exposed to venetoclax (100 nM) and idasanutlin
(100 nM) alone or in combination for time periods indicated. Actin








































































Fig. 7 shRNA inhibition of Mcl-1 gene expression in MV4-11 cells a
Western blot analysis of Mcl-1 protein expression and b viability
of shRNA transduced cells measured by trypan blue exclusion,
confirming that Mcl-1 contributes significantly to AML cell survival
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Notably, for the OCI-AML-3 cell line, little inhibitory
effect was seen in response to venetoclax treatment and
this may be due to BH3 mimetic resistance previously
observed with this cell line (data not shown). However,
combination treatment induced substantial cell death in
this cell line, overcoming resistance to venetoclax and
removing the cell cycle dependency of idasanutlin activ-
ity (Figs. 1 and 2 and Additional file 2).
In contrast to the in vitro studies, more modest
growth inhibition was seen when the single-agent inhibi-
tors were administered to in vivo human AML xenograft
models. Venetoclax had no effect in either the subcuta-
neous or orthotopic MV4-11 models and neither inhibi-
tor showed substantial improvements in survival versus
the vehicle control in the MOLM-13 model, although
venetoclax was marginally better than idasanutlin. This
low activity for single-agent treatment may be due to the
aggressive nature of these in vivo AML models, particu-
larly the MOLM-13 orthotopic model, or due to poor
tumor penetration of the compounds. In spite of this
and in line with our results in vitro, combination treat-
ment led to superior tumor growth inhibition and sub-
stantial ILS compared with the vehicle control and
single-agent therapies.
Our data confirm and add on to previously pub-
lished findings. Saiki et al. [31] showed synergistic ef-
fects when combining MDM2 antagonists and the
dual Bcl-2/Bcl-xL inhibitors ABT-737 and ABT-263 in
solid and hematologic tumor cell lines. Using the Bcl-
2-selective inhibitor ABT-199 as combination partner,
activity was mainly restricted to hematological cell
lines. The authors concluded that Bcl-xL inhibition is
essential for synergy with MDM2 antagonists in solid
tumor cell lines, while selective Bcl-2 inhibition in
hematologic cell lines is sufficient [31]. Moreover, an
earlier study of dual MDM2 and Bcl-2 inhibition with
ABT-737 and nutlin-3 (tool compounds used for in
vitro studies) showed the feasibility of combining
MDM2 and Bcl-2 inhibitors in AML [32]. In that
study, the individual effects of MDM2 and Bcl-2 in-
hibition were shown to be cell cycle-specific with
nutlin-3a inducing apoptosis predominantly in the
G2/M phase of the cell cycle while ABT-737 induced
apoptosis predominantly while cells were in G1. Com-
bination treatment removed the cell cycle-dependent
effects of treatment, with the authors proposing that
this could account, in part, for the synergy observed.
Similar cell cycle effects were seen in the current
study in response to single-agent exposure to the
clinical-grade compounds idasanutlin and venetoclax.
Treatment with idasanutlin alone led to G1 cell cycle
arrest, with little evidence of apoptosis until subse-
quent cycles of replication. With venetoclax treat-
ment, cells continued to divide and apoptosis was
induced during each round of replication. Combin-
ation treatment resulted in direct induction of cell
death without any further cell division. Thus, the cell
cycle-independent activity of the combination treat-
ment could contribute to the synergy, which mani-
fests as an acceleration of cell death kinetics.
Gene expression analysis in the MOLM-13 cell line
further highlighted the different mechanisms of action of
venetoclax and idasanutlin. The expression of far fewer
genes was altered in response to venetoclax treatment
compared with idasanutlin or combination treatment,
reflecting the fact that Bcl-2 inhibition and subsequent
mitochondrial apoptosis is mediated mainly through
protein-protein interactions while p53 signaling is medi-
ated at the protein and transcriptional level. Upstream
regulator analysis of gene expression changes in re-
sponse to idasanutlin and combination treatment identi-
fied TP53 pathway activation and CCND1 pathway
inhibition as being significant (Fig. 5), which is as ex-
pected based on the cell cycle inhibition observed in the
cell cycle kinetic experiments (Fig. 4).
The concept that Mcl-1 might be an important medi-
ator of AML cell survival has been described in previous
work [33]. By shRNA and Western blot studies, we con-
firmed that Mcl-1 inhibition appears to play a significant
role in maintaining viability of AML cells (Figs. 6 and 7).
Moreover, we demonstrated for the first time that the
synergistic effects seen in vitro in combination treatment
with venetoclax and idasanutlin is due to accelerated
Mcl-1 downregulation and subsequent induction of
apoptosis (Fig. 6). This is notable, as Mcl-1 expression is
also associated with resistance to BH3 mimetics [34].
Suppression of Mcl-1 expression here in response to ida-
sanutlin treatment may increase the sensitivity of AML
cells to venetoclax. Mcl-1 degradation through activated
caspases at the timepoints investigated is rather unlikely,
since Mcl-1 in MOLM-13 cells was still detectable after
cleaved-caspase-3 was already induced (Fig. 6a). Our
findings are consistent with a previous study that
showed decreased expression of Mcl-1 in response to
cyclin-dependent kinase inhibition which led to in-
creased sensitivity of human leukemia cells to the BH3
mimetic ABT-737 [35].
Conclusions
In this study, we provided evidence that in human AML
models, venetoclax and idasanutlin display a strongly su-
perior effect when administered in combination to pro-
vide substantial improvements in anti-tumor activity
versus the respective single-agent treatments. Combin-
ation treatment removed the cell cycle dependency of
idasanutlin response leading to an acceleration of cell
death kinetics versus single-agent treatment. It also led
to enhanced inhibition of the anti-apoptotic protein
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Mcl-1, a known resistance factor to BH3 mimetics in-
cluding venetoclax. Given the clinical efficacy that has
already been shown for idasanutlin and venetoclax as
single agents in AML [29, 30], these findings support the
further testing of this novel combination in clinical stud-
ies. In addition, pre-selecting patient populations on the
basis of p53 status and Bcl-2 expression might signifi-
cantly accelerate clinical development of this combin-
ation [36]. To this end, a clinical study with idasanutlin
and venetoclax is being initiated currently.
Additional files
Additional file 1: Vector sequences for Mcl-1-targeting shRNA.
(DOCX 13 kb)
Additional file 2: Flow cytometric analysis of OCI-AML-3 cells following
exposure to venetoclax and idasanutlin alone or in combination for 72 h.
BrdU was added for the last 24 h as described in the “Methods” section.
The top panel shows PI fluorescence versus SSC-A with gating for normal
nuclei, abberant (SSC-A high) nuclei and subG1 events. The bottom panel
shows cell cycle distribution for these subsets stained with Hoechst
33258 and PI. As expected, idasanutlin induced cell cycle arrest in G1, first
cycle, while venetoclax had little or no effect on cell cycle progression
and viability. The combination of both compounds lead to an increase of
SSC-A high events. Events in subG1 were mainly derived from aberrant
nuclei, while some SSC-A high nuclei are still intact. The decrease in
Hoechst 33258 fluorescence indicated that DNA degradation has already
started, confirming that these cells were in the early stages of apoptosis.
PI, propidium iodide; SSC-A, side scatter area. (PDF 73 kb)
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